Context Therapeutics (NASDAQ:CNTX) Receives “Overweight” Rating from Piper Sandler

Piper Sandler reiterated their overweight rating on shares of Context Therapeutics (NASDAQ:CNTX) in a research note released on Thursday morning,Benzinga reports. The firm currently has a $4.00 price objective on the stock, down from their prior price objective of $4.50.

Several other brokerages also recently commented on CNTX. D. Boral Capital reaffirmed a “buy” rating and issued a $9.00 target price on shares of Context Therapeutics in a research note on Thursday, May 8th. HC Wainwright reissued a “buy” rating and set a $5.00 price target on shares of Context Therapeutics in a research report on Friday, March 21st. Finally, William Blair restated an “outperform” rating on shares of Context Therapeutics in a research report on Tuesday, April 29th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $5.50.

Context Therapeutics Trading Down 0.5%

CNTX opened at $0.65 on Thursday. Context Therapeutics has a 12 month low of $0.49 and a 12 month high of $2.75. The business’s 50-day moving average price is $0.72 and its 200-day moving average price is $0.85. The company has a market cap of $58.42 million, a P/E ratio of -2.10 and a beta of 1.86.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.05). Equities research analysts forecast that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.

Insider Transactions at Context Therapeutics

In related news, CEO Martin A. Lehr bought 100,000 shares of the business’s stock in a transaction dated Monday, June 9th. The shares were purchased at an average price of $0.70 per share, with a total value of $70,000.00. Following the purchase, the chief executive officer now owns 920,190 shares of the company’s stock, valued at approximately $644,133. This trade represents a 12.19% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Jennifer Lynn Minai-Azary purchased 40,010 shares of Context Therapeutics stock in a transaction that occurred on Friday, June 6th. The shares were bought at an average price of $0.64 per share, for a total transaction of $25,606.40. Following the transaction, the chief financial officer now directly owns 80,010 shares of the company’s stock, valued at $51,206.40. This trade represents a 100.03% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 160,010 shares of company stock worth $107,206. 2.80% of the stock is currently owned by insiders.

Institutional Trading of Context Therapeutics

Several large investors have recently bought and sold shares of the company. Jane Street Group LLC purchased a new position in shares of Context Therapeutics during the 4th quarter worth approximately $29,000. Citadel Advisors LLC bought a new stake in shares of Context Therapeutics during the fourth quarter valued at approximately $31,000. Shay Capital LLC purchased a new stake in Context Therapeutics in the fourth quarter worth $52,000. Landscape Capital Management L.L.C. bought a new position in Context Therapeutics in the fourth quarter worth $94,000. Finally, Walleye Capital LLC raised its holdings in Context Therapeutics by 51.7% in the fourth quarter. Walleye Capital LLC now owns 166,306 shares of the company’s stock worth $175,000 after purchasing an additional 56,651 shares in the last quarter. 14.03% of the stock is owned by institutional investors.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.